Entrada Therapeutics (TRDA) Operating Leases (2022 - 2026)

Entrada Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $45.5 million for Q1 2026.

• In Q1 2026, Operating Leases fell 9.94% year-over-year to $45.5 million; the TTM figure through Mar 2026 stood at $45.5 million (down 9.94% YoY), while the FY2025 annual figure was $46.8 million, down 9.4% from the prior year.
• Operating Leases was $45.5 million for Q1 2026 at Entrada Therapeutics, down from $46.8 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $73.0 million in Q2 2023 to a low of $16.2 million in Q1 2023.
• Historically, Operating Leases has averaged $44.8 million across 5 years, with a median of $49.3 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Operating Leases plunged 32.07% in 2023, then surged 258.28% in 2024.
• A 5-year view of Operating Leases shows it stood at $17.5 million in 2022, then surged by 244.1% to $60.3 million in 2023, then declined by 14.38% to $51.6 million in 2024, then declined by 9.4% to $46.8 million in 2025, then fell by 2.83% to $45.5 million in 2026.
• The last three Operating Leases figures came in at $45.5 million (Q1 2026), $46.8 million (Q4 2025), and $48.0 million (Q3 2025), per Business Quant data.